LXRX - Bullish But Risky Move. Pullback Coming

11 sept. 2019Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. It drug candidates include XERMELO, Sotagliflozin, LX2761, and LX9211. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.

SHORT INTEREST
7.74M 08/15/19

P/E Current
-1.51

P/E Ratio (with extraordinary items)
-2.05

Average Recommendation: OVERWEIGHT

Average Target Price: 8.00